Prosecution Insights
Last updated: November 04, 2026
Application No. 18/559,891

ACID ADDITION SALT OF ROCK INHIBITOR, AND CRYSTAL FORM, COMPOSITION AND PHARMACEUTICAL USE THEREOF

Non-Final OA §103§112§DOUBLEPATENT
Filed
Nov 09, 2023
Priority
May 14, 2021 — CN 202110533087.9 +2 more
Examiner
HIRAKIS, SOPHIA P
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Wuhan Ll Science And Technology Development Co. Ltd.
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
35 granted / 61 resolved
-2.6% vs TC avg
Strong +70% interview lift
Without
With
+69.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
40 currently pending
Career history
99
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
34.7%
-5.3% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 61 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application, filed 11/09/2023, is a 371 filing of PCT/CN2022/092622, filed 05/13/2022, which claims foreign priority to CN202210500178.7, filed 05/07/2022, and CN202110533087.9, filed 05/14/2021. It is noted however that applicant has not filed a certified translation of the foreign applications as required by 37 CFR §1.55. Therefore, applicant is not entitled to the effective filing dates associated with the foreign priority documents. Preliminary Amendments and Claim Status The preliminary amendment filed on 11/09/2023 is acknowledged and entered. Claims 3-6 and 8-11 are amended; Claims 13 and 14 are added. Claims 1-14 are pending and are under prosecution. Information Disclosure Statement The Information Disclosure Statement filed on 11/09/2023 and 12/26/2025 are acknowledged and found to be in compliance with the provisions of 37 CFR § 1.97. Accordingly, the information disclosure statements are considered. Restriction/Election Applicant’s election without traverse of Group I in the reply filed on 04/15/2026 is acknowledged. Applicant’s election of the following specific species is also acknowledged: Species A: fumaric acid salt of compound A Species B: having characteristic peaks at peaks at 2θ angles of 3.90°±0.20°, 13.93°±0.20°, 16.86°±0.20°, and 26.37°±0.20° by X-ray powder diffraction using Cu-Kα radiation Species C: compound A and the fumaric acid are in a molar ratio of 2:1 Species D: an anhydrate Species E: the second active ingredient is selected from other ROCK inhibitors With respect to the arguments filed on 04/15/2026, regarding the use of a prior art disclosure for the restriction requirement, Applicant correctly surmised that the WO’795 was the intended document to be used for prior art set forth for the restriction requirement. However, in order to circumvent any forthcoming issues with co-ownership of the prior art documents, the disclosure by Curtin et al. (WO2012067965A1, published May 24, 2012), hereinafter Curtin is hereby placed on the record as teaching the shared technical feature of the instant claims. Curtin teaches a compound of Formula (Ic) and a pharmaceutically acceptable salt thereof is taught, which shares a common structural core with the compound of the instant claims (claims 1-2). The compounds of the prior art by Curtin are classified as a ROCK inhibitors, corresponding directly with the compounds (Abstract). Therefore, the shared technical feature of the instant claims does not make a contribution over the prior art of record. Therefore, the claims lack unity of invention. Accordingly, the requirement for restriction is deemed proper, and hereby made FINAL. With respect to the arguments regarding the use of the prior art for which common ownership is declared, Applicant states: “at the time the instant application was filed, neither the WO’878 nor the WO’795 were published prior to the earliest effective filing date of the instant application”, and both were “owned by Wuhan LL Science and Technology Development Co., LTD at the time the instant application was filed.” In order for Applicant to properly invoke common ownership to disqualify a U.S. patent document as prior art under 35 U.S.C. § 102(a)(2), Applicant must submit the required statement that the subject matter in the U.S. patent document and the claimed invention were, not later than the effective filing date of the claimed invention, owned by, or subject to an obligation of assignment, to the same person. See 37 CFR § 1.104(c)(4)(i). The statement concerning common ownership should be clear and conspicuous (e.g., on a separate piece of paper or in a separately labeled section). The statement must be signed in accordance with 37 CFR § 1.33(b). The To clarify, a proper statement should address common ownership in terms of the effective filing date, and not “at the time the instant application was filed.” Statements regarding “the time of filing” apply to pre-AIA requirements. Post AIA , the focus on prior art documents is in terms of on or before “the effective filing date.” Statements in terms of publication are not applicable. Accordingly, the statement submitted by Applicant is insufficient to invoke common ownership in order to disqualify the documents as prior art under 35 U.S.C. § 102(a)(2). In accordance with the MPEP § 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. As per MPEP § 803.02, the Examiner will determine whether the entire scope of the claims is patentable. Applicant’s elected species does not make a contribution over the prior art of record. Status of Claims Claims 1-14 are pending in the instant application. Claims 3, 4, 6, 7, and 9-14 are withdrawn from further consideration pursuant to 37 CFR § 1.142(b), as being drawn to a non-elected invention and species. Therefore, claims 1, 2, 5, and 8 read on an elected invention and species and are therefore under consideration in the instant application. Drawings The drawings filed on 11/09/2023 are objected to under 37 CFR § 1.83 (a) for the following reasons: The different data types are indistinguishable in Figures 2, 5, 8, 12, 13, 16, 19, 22, 31, 34, 37, 39, and 40-43. The original figures may rely on color-coding of the data, a feature not available in the black and white drawings. The figures must be remade with shapes or line-types used to describe the different data displayed within the same figures. The different data types are indistinguishable in Figures 40-42 (top panels). The figures lack a figure key to describe the different data types. The figures must be remade with a figure key describing the different types of data found within the same figures. Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). Corrected drawing sheets in compliance with 37 CFR § 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR § 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 U.S.C. § 112 The following is a quotation of 35 U.S.C. § 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. § 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 2, 5, and 8 are rejected under 35 U.S.C. § 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 2, 5, and 8 recite numerous instances of limitations which are “preferably” included. The use of “preferably” renders the claims indefinite because there is a question or doubt as to whether the feature introduced by language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. As there are numerous instances of the language “preferably” recited in the same claim, Applicant is expected to address each instance individually by way of amendment. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claims 2, 5, and 8 recite numerous broad limitations, as well as narrow limitations within the same claim. For example, claim 5 recites the broad recitation “compound A and the fumaric acid according to a molar ratio of 1:1 or 2:1,” and the claim also recites “’ preferably, in the fumarate crystal form I, compound A and the fumaric acid are in a molar ratio of 2:1” which is the narrower statement of the range/limitation. The claims are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. As there are numerous instances of narrow and broad ranges recited within the same claim, Applicant is expected to address each instance individually by way of amendment. Regarding claims 2 and 8, the phrase "for example" and “e.g.” render the claims indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim 8 recites, “the pharmaceutical composition further comprises a second active ingredient, wherein, for example, the second active ingredient is one, two or more of other ROCK inhibitors, tyrosine kinase inhibitors, tyrosinase inhibitors, inhibitors of profibrotic cytokines, serum amyloid P inhibitors, autotaxin-lysophosphatidic acid pathway inhibitors, GPR40 agonists, GPR84 antagonists, anti-acid drugs, and antibiotics.” As in the case of the broad and narrow limitations with the same claim, the claim is considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim Rejections - 35 U.S.C. § 103 The following is a quotation of pre-AIA 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 2, and 8 are rejected under 35 U.S.C. § 103 as being unpatentable over Li et al. (WO 2021093795 A1, effectively filed November 15, 2019, for the purpose of 35 U.S.C. § 102 (a) (2), cited in applicant IDS filed 11/09/2023), hereinafter Li. Citations are directed to the PatentScope translation of the foreign document. Applicant cannot rely upon the certified copy of the foreign priority application to overcome this rejection because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. The applied reference has a common applicant with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 103 might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C.102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B); or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. The instant claims are drawn to a fumaric acid salt of compound A. Li teaches compound A, as compound T345 (claim 6), also known as CAS Registry Number: RN 2643334-76-1. [Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 2643334-76-1, Entered STN: 08 Jun 2021]. Li teaches wherein a pharmaceutically acceptable salt may be an acid addition salt of fumaric acid (paragraph [0201], see instant claims 1 and 2). Li further teaches wherein the molar ratio of the compound to the acid can be 4 :1~1:4, such as 3:1, 2:1, 1:1, 1:2, 1:3, etc. (paragraph [0204], see instant claim 2). Finally, Li teaches a pharmaceutical composition comprising a compound taught, wherein the pharmaceutical composition can contain more than one compound according to the language “at least one of a therapeutically effective amount of a compound represented by Formula (I)” (claim 10). Therefore, the pharmaceutical composition taught by Li may comprise a second ROCK inhibitor, as instantly elected (see instant claim 8). The prior art is not anticipatory insofar as these combinations must be selected from various lists/locations in the reference. It would have been obvious, however, to make the combination since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results to one of ordinary skill in the art (see MPEP § 2143 (I)(A)). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, and 8 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. US 12735414 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the patent teaches instantly claimed Formula (A) as compound T345 (see patented claim 4), and a pharmaceutically acceptable salt thereof (claim 5). Choosing from a finite number of solutions, it would’ve been obvious to arrive at a fumaric acid salt of the compound, therefore rendering the instant claims obvious over the patented claims. Correspondence No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sophia P. Hirakis whose telephone number is +1 (571) 272-0118. The examiner can normally be reached within the hours of 5:00 am to 5:00pm EST, Monday through Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C. Milligan can be reached on +1 (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is +1 (571) 273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call +1 (800) 786-9199 (IN USA OR CANADA) or +1 (571) 272-1000. /SOPHIA P HIRAKIS/Examiner, Art Unit 1623 /VALERIE RODRIGUEZ-GARCIA/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Nov 09, 2023
Application Filed
Apr 15, 2026
Response after Non-Final Action
Oct 20, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12741030
VANILLIN DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1
3y 12m to grant Granted Sep 22, 2026
Patent 12729213
SMALL MOLECULE DEGRADERS OF STAT3
4y 11m to grant Granted Sep 08, 2026
Patent 12655131
PHARMACEUTICAL COMPOUNDS FOR USE IN TREATING CANCER
4y 3m to grant Granted Jun 16, 2026
Patent 12649715
INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION
3y 8m to grant Granted Jun 09, 2026
Patent 12636267
NICLOSAMIDE DELAYED-RELEASE COMPOSITION AND ANTIVIRAL USE THEREOF
3y 11m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
99%
With Interview (+69.8%)
3y 8m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 61 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month